Brentuximab vedotin (BV) is an antibody-drug conjugate composed of a CD30-directed monoclonal antibody and monomethyl auristatin E \[[@ref1]\]. BV monotherapy showed good response rates for cases of refractory and relapsed anaplastic large cell lymphoma (ALCL), but only a few case reportsare available for cutaneous localized ALCL (cALCL). We herein report the treatment with BV of relapsed cALCL with an excellent response. An 82-year-old female with relapsed cALCL had generalized erythema accompanied by desquamation and could not extend her fingers enough ([Figure 1](#f1){ref-type="fig"}), with no lymph node lesions. Due to the previous treatment with radiation, steroid ointment, and systemic chemotherapy, we chose BV monotherapy for her, dosing at 1.8 mg/kg every 21 days. After the third infusion, her generalized erythemaand her finger movement were improved ([Figure 2](#f2){ref-type="fig"}). She did not have any severe adverse effects or infusion reaction except for hematologic toxicity (leukocytopenia). She has finished 6 courses of BV infusion and maintained remission of skin lesions. There are several reports that showed the effectiveness of BV treatment for cALCL \[[@ref2],[@ref3]\], but the optimal treatment interval and cycles, and the necessity of maintenance therapy by using BV, are unclear. Further studies are needed to evaluate BV treatment in cases of cALCL.
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